摘要:
A solid, water-soluble complex comprising:a) a polysiloxane of the formula: ##STR1## wherein n is from 2 to 6; a is from 8 to 25; and b is from 0 to 25; and the oxyalkylene groups may be random or block mixtures; y is from 0 to 5; x is from 1 to 5; and R is selected from the group consisting of hydrogen, C.sub.1 -C.sub.4 alkyl, and a C.sub.1 -C.sub.4 alkyl ester; or ##STR2## wherein A is a linear or branched alkyl having 6 to 30 carbon atoms; G is a glycol moiety of the formula --R'(OCH.sub.2 CH.sub.2).sub.m OR" wherein R' is a divalent alkylene group having 2 to 6 carbon atoms; R" is selected from the group consisting of hydrogen, C.sub.1 -C.sub.4 alkyl, and a C.sub.1 -C.sub.4 alkyl ester; m is 8 to 100; y is 0 to 5; X is 0.1 to 2.5; and z is 0.1 to 5.0;b) a complex-forming agent of the formula: ##STR3## wherein X is O, S, Se, or Te, and c) a readily clathratable polyoxyethylene, e.g. a tridecyl alcohol ethoxylate having eight or more oxyethylene units.These complexes are useful as adjuvants for dry agricultural chemicals such as pesticides and/or fertilizers. The complex may also contain a non-clathratable polyoxyethylene, e.g. a block copolymer of ethylene oxide and propylene oxide having a ratio of ethylene oxide to propylene oxide of not more than about 0.87:1.
摘要:
Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, n, m, o, p, and q are as hereinafter set forth,and, when R.sub.2 is hydrogen, pharmaceutically acceptable salts thereof with bases, are described. The compounds of formula 1 are potent inhibitors of phospholipases A.sub.2 (PLA.sub.2 's) and are therefore useful in the treatment of inflammatory diseases, such as psosiasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia/reperfusion, and trauma induced inflammation, such as spinal cord injury.
摘要:
A process for the preparation of substituted urea derivatives, and compositions and concentrates for the same purpose are disclosed. According to the process the substituted urea derivatives of formula (I) ##STR1## wherein R is hydrogen, alkyl, aryl, cycloalkyl or aralkyl, R.sup.1 and R.sup.2 are hydrogen, alkyl, alkenyl, alkinyl, alkoxy, oxyalkyl, cycloalkyl, aralkyl, alkoxycarbonylalkyl, aryl or heteroaryl, or R.sup.1 and R.sup.2 together with the adjacent nitrogen atom may form a saturated or unsaturated heterocycle, or a condensed and/or substituted ring system, and said heterocycle or said condensed and/or substituted ring system may contain also a sulfo group,can be manufactured by reacting an amine of formula (II) ##STR2## with an N-carbamoyl-benzoic acid sulfimide derivative of formula (III) ##STR3## The disclosed N-acylating composition comprises of from 3 to 60% by weight, preferably of from 5 to 50% by weight sulfimide derivative of formula (III), of from 97 to 40% by weight, preferably of from 95 to 50% by weight solvent, and if desired, an organic or inorganic base.The disclosed N-acylating concentrate comprises of from 60 to 95.5% by weight N-acylating agent of formula (III) and of from 4.5 to 40% by weight additives.
摘要:
THEIR TAUTOMERIC FORMS AND ACID ADDITION SALTS THEREOF ARE POTENT MYOCARDIAL CATECHOLAMINE DEPLETORS AS WELL AS HYPOTENSIVE AND ANTIHYPERTENSIVE AGENT.
(R3-N=C(-NH-R4)-CNH2N-),R1,R2-ISOTHIAZOLE
SUBSTITUTED ISOTHIAZOLYL-ALKYL-GUANIDINES OF THE FORMULA
摘要:
A method for the production of a urea ammonium sulphate (UAS) composition in a pipe reactor comprising at least a reactor section, the method comprising:
combining in the reactor continuous feeds of at least one of sulphuric acid and ammonium bisulphate, at least one of ammonia and ammonium carbamate, and urea; and including a viscosity-reducing agent selected from water soluble aluminum salts in at least one of the continuous feeds, thereby forming the urea ammonium sulphate (UAS composition, wherein the UAS composition comprises 1 to 40 weight % of ammonium sulphate (AS) relative to the total weight of the UAS composition.
摘要:
Integrated process for the production of urea and urea-ammonium nitrate, comprising: reacting ammonia and carbon dioxide to form a reaction mixture (4) containing urea and unconverted materials, and also comprising the recovery of unconverted materials in a first recovery stage at a first pressure and in a second recovery stage at a second pressure, wherein ammonia-containing offgas (19) released by said second recovery stage are condensed at said second pressure, and said condensed offgas (20) are recycled to said first recovery stage.
摘要:
Mew tranilast complexes and new tranilast cocrystais are disclosed. These include all tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-amtnoben2oic acid complex, a 1:1 tranilast 4-am!nobers2oic acid cocrystal, a 1:1 tranilast 2,4-di′hydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystais as well as the pharmaceutical compositions are disclosed.
摘要:
There is provided a mixture having a freezing point of up to 100° C. formed by a process comprising the step of contacting: (A) from 1 to 2 equivalents of a compound of formula (I) AlX3 (I) wherein each X independently represents Cl, Br or F; with (B) 1 equivalent of a compound of formula (II) R1—C(O)—N(R2)(R3) (II) wherein R1 to R3 have meanings given in the description. There is also provided further mixtures containing additional components, as well as methods of using the mixtures in various applications, such as for the electroreduction of the mixtures to produce aluminum metal.
摘要:
Mew tranilast complexes and new tranilast cocrystals are disclosed. These include all tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-amtnoben2oic acid complex, a 1:1 tranilast 4-am!nobers2oic acid cocrystal, a 1:1 tranilast 2,4-di′hydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystais as well as the pharmaceutical compositions are disclosed.
摘要:
Oral smokeless tobacco products and oral smokeless non-tobacco snuff products include carbamide or carbamide salt(s). The carbamide salt is chosen from the group including carbamide calcium sulphate [4(CH4N2O).CaSO4], carbamide magnesium sulphate [6(CH4N2O).MgSO4.2H2O] and carbamide sodium chloride [CH4N2O).NaCl.H2O]. Moreover, carbamide or carbamide salt(s) are used in the manufacturing of oral smokeless tobacco products or oral smokeless non-tobacco snuff products.